JPH04346926A - Syrup agent - Google Patents
Syrup agentInfo
- Publication number
- JPH04346926A JPH04346926A JP14685291A JP14685291A JPH04346926A JP H04346926 A JPH04346926 A JP H04346926A JP 14685291 A JP14685291 A JP 14685291A JP 14685291 A JP14685291 A JP 14685291A JP H04346926 A JPH04346926 A JP H04346926A
- Authority
- JP
- Japan
- Prior art keywords
- ascorbic acid
- syrup
- sodium
- active ingredient
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006188 syrup Substances 0.000 title claims abstract description 30
- 235000020357 syrup Nutrition 0.000 title claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 77
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 38
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 37
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003268 Vitamin C Natural products 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract description 4
- 235000019154 vitamin C Nutrition 0.000 abstract description 4
- 239000011718 vitamin C Substances 0.000 abstract description 4
- 239000003925 fat Substances 0.000 abstract description 3
- 239000003921 oil Substances 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 abstract description 2
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 abstract description 2
- 235000011009 potassium phosphates Nutrition 0.000 abstract description 2
- 230000003405 preventing effect Effects 0.000 abstract description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract description 2
- 235000017550 sodium carbonate Nutrition 0.000 abstract description 2
- 235000011121 sodium hydroxide Nutrition 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 12
- 235000010378 sodium ascorbate Nutrition 0.000 description 12
- 229960005055 sodium ascorbate Drugs 0.000 description 12
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 ascorbic acid monophosphate Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000000996 L-ascorbic acids Chemical class 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- GJQWCDSAOUMKSE-STHAYSLISA-N 2,3-diketogulonic acid Chemical compound OC[C@H](O)[C@@H](O)C(=O)C(=O)C(O)=O GJQWCDSAOUMKSE-STHAYSLISA-N 0.000 description 1
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001242 enediol group Chemical group 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は安定にアスコルビン酸類
を含有するシロップ剤に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a syrup stably containing ascorbic acids.
【0002】0002
【従来の技術】アスコルビン酸は皮膚色素沈着防止作用
等の特異な生理活性により、医薬品、化粧品に使用され
ている他、食品、医薬部外品にビタミンCとして、或は
、油脂、食品等の酸化防止剤として用いられるなど極め
て広い分野で供されている。[Prior Art] Ascorbic acid is used in pharmaceuticals and cosmetics due to its unique physiological activities such as preventing skin pigmentation, and is also used as vitamin C in foods and quasi-drugs, or as vitamin C in oils, fats, foods, etc. It is used in a wide range of fields, including as an antioxidant.
【0003】しかし、アスコルビン酸はその分子構造中
にエンジオール基を有し、特に2位及び3位の炭素原子
に結合したエノール基は容易に水素原子を失い酸化され
ケト型に互変異性し、更には、ジケトグロン酸、シュウ
酸、スレオニン等に分解され着色する。従って、アスコ
ルビン酸は非常に不安定な特質があり、ことに水溶液中
ではその傾向が強い。更に、アルカリ性及び重金属存在
下においては破壊が著しく促進される。However, ascorbic acid has an enediol group in its molecular structure, and especially the enol groups bonded to the 2- and 3-position carbon atoms easily lose hydrogen atoms and are oxidized to become tautomerized to the keto form. Furthermore, it decomposes into diketogulonic acid, oxalic acid, threonine, etc. and becomes colored. Therefore, ascorbic acid has the property of being very unstable, especially in an aqueous solution. Furthermore, destruction is significantly accelerated in the presence of alkalinity and heavy metals.
【0004】そのため水系組成物への配合に際しては、
従来から種々の安定化策が採用されている。例えば、シ
クロデキストリンやリポソームその他油脂類で包んだり
、グリセリン等の多価アルコールの非水系水溶性基剤に
配合したりしている。[0004] Therefore, when blending into an aqueous composition,
Various stabilization measures have been adopted in the past. For example, it may be wrapped in cyclodextrin, liposome, or other oils or fats, or it may be blended with a non-aqueous water-soluble base of polyhydric alcohol such as glycerin.
【0005】[0005]
【発明が解決しようとする課題】しかし、これら安定化
策はアスコルビン酸としての活性の低下及びビタミンC
作用保持、副作用、安定性の面で未だ満足すべきもので
はない。従って、アスコルビン酸又はその塩類又はその
誘導体を安定に配合したシロップ剤の開発が期待されて
いる状況にある。[Problems to be Solved by the Invention] However, these stabilization measures lead to a decrease in the activity of ascorbic acid and a decrease in the activity of vitamin C.
It is still unsatisfactory in terms of retention of action, side effects, and stability. Therefore, the development of a syrup formulation stably containing ascorbic acid, its salts, or its derivatives is expected.
【0006】[0006]
【課題を解決するための手段】かかる実情に鑑み、 本
発明者等は、安定なアスコルビン酸含有シロツプ剤を開
発すべく鋭意研究を行った結果、炭酸水素ナトリウム等
によってシロップ剤のpHを6. 0〜8. 0の範囲
に調整することによりアスコルビン酸の含量低下を防止
できることを見い出し、本発明を完成するに至った。[Means for Solving the Problems] In view of the above-mentioned circumstances, the present inventors conducted intensive research to develop a stable ascorbic acid-containing syrup, and as a result, the pH of the syrup was adjusted to 6.0 with sodium bicarbonate or the like. 0-8. It was discovered that a decrease in the content of ascorbic acid can be prevented by adjusting it to a range of 0, and the present invention was completed based on this finding.
【0007】すなわち、 本発明はアスコルビン酸又は
その塩類又はその誘導体を有効成分とし、かつpHが6
. 0〜8. 0の範囲に調整されていることを特徴と
するシロップ剤に関する。That is, the present invention uses ascorbic acid or its salts or its derivatives as an active ingredient, and has a pH of 6.
.. 0-8. The present invention relates to a syrup characterized in that the syrup is adjusted to a range of 0.
【0008】シロップ剤のpHが上記範囲外にある場合
は経時的に性状の変化及び分解がおこり、冷所保存など
の規制が必要となるという問題がある。従って、本発明
のシロップ剤において、炭酸水素ナトリウム及びリン酸
塩等の含有量は、シロップ剤が上記pHの範囲内にある
ように決定される。[0008] If the pH of the syrup is outside the above range, there is a problem that the properties change and decompose over time, making it necessary to store it in a cool place. Therefore, in the syrup of the present invention, the contents of sodium bicarbonate, phosphate, etc. are determined so that the syrup is within the above pH range.
【0009】本発明においてアスコルビン酸の塩及び誘
導体としては、アスコルビン酸ナトリウム、またはアル
コルビン酸カリウムのようなアスコルビン酸の3位の炭
素の水酸基をアルカリ金属で中和したモノアルカリ金属
塩、及びアスコルビン酸モノステアレート、アスコルビ
ン酸モノパルミテート、アスコルビン酸モノオレエート
、またはアスコルビン酸モノホスフェートのようなアス
コルビン酸モノエステル誘導体、アスコルビン酸ジステ
アレート、アスコルビン酸ジパルミテート、アIn the present invention, the salts and derivatives of ascorbic acid include monoalkali metal salts obtained by neutralizing the hydroxyl group at the 3-position carbon of ascorbic acid with an alkali metal, such as sodium ascorbate or potassium ascorbate, and ascorbic acid. Ascorbic acid monoester derivatives such as monostearate, ascorbic acid monopalmitate, ascorbic acid monooleate, or ascorbic acid monophosphate, ascorbic acid distearate, ascorbic acid dipalmitate, a
【001
0】スコルビン酸ジオレエート、またはアスコルビ酸ジ
ホスフェートのようなアスコルビン酸ジエステル誘導体
、アスコルビン酸トリステアレート、アスコルビン酸ト
リパルミテートまたはアスコルビン酸トリホスフェート
のようなアスコルビン酸トリエステル誘導体、6ーステ
アロイルアスコルビン酸、または6ーパルミトイルアス
コルビン酸のようなアスコルビン酸のアシル誘導体等の
アスコルビン酸誘導体が挙げられる。001
0. Ascorbic acid dioleate or ascorbic acid diester derivatives such as ascorbic acid diphosphate, ascorbic acid triester derivatives such as ascorbic acid tristearate, ascorbic acid tripalmitate or ascorbic acid triphosphate, 6-stearoyl ascorbic acid, Alternatively, ascorbic acid derivatives such as acyl derivatives of ascorbic acid such as 6-palmitoyl ascorbic acid can be mentioned.
【0011】シロップ剤の原料としては、白糖、マンニ
トール、ソルビトール等の糖類及びサッカリン等の甘味
剤が挙げられる。PH調整剤としては炭酸水素ナトリウ
ム、炭酸ナトリウム、水酸化ナトリウムまたはリン酸カ
リウム等が挙げられる。Raw materials for syrups include sugars such as white sugar, mannitol and sorbitol, and sweeteners such as saccharin. Examples of the pH adjuster include sodium hydrogen carbonate, sodium carbonate, sodium hydroxide, and potassium phosphate.
【0012】また、本発明のシロップ剤には上記必須成
分に加えて、必要に応じて、たとえば、アセトアミノフ
ェン、フェナセチン、アスピリンなどの解熱剤、マレイ
ン酸クロルフェニラミンなどの抗ヒスタミン剤、塩酸メ
チルエフェドリン、リン酸コデインなどの鎮咳剤、セネ
ガエキスなどの生薬類のような薬効成分、パラオキシ[0012] In addition to the above-mentioned essential ingredients, the syrup of the present invention may also contain, if necessary, antipyretics such as acetaminophen, phenacetin, and aspirin, antihistamines such as chlorpheniramine maleate, methylephedrine hydrochloride, Medicinal ingredients such as antitussives such as codeine phosphate, herbal medicines such as Senega extract, paraoxygen
【
0013】安息香酸メチルなどの保存剤、ストロベリー
フレイバーなどの芳香剤、メチルセルロース等の粘稠剤
、グリセリン脂肪酸エステルなどの乳化剤、または食用
赤色102号などの着色剤等を適宜組合せ使用してもよ
い。その配合量は、上記本発明の必須成分が本発明の目
的を逸しない程度を用いればよい。[
Preservatives such as methyl benzoate, fragrances such as strawberry flavor, thickeners such as methylcellulose, emulsifiers such as glycerin fatty acid esters, coloring agents such as Food Red No. 102, etc. may be used in appropriate combinations. The blending amount may be such that the above-mentioned essential components of the present invention do not deviate from the purpose of the present invention.
【0014】本発明のシロップ剤の調製法としては、た
とえば有効成分としてアスコルビン酸ナトリウム、pH
調整剤として炭酸水素ナトリウムを窒素置換下で、精製
水に加え溶かし、それに別に矯味剤、保存剤、または必
要に応じて他の薬効成分にそれぞれ精製水を加え、加温
などして溶かしたものを窒素置換下で混合攪拌し、適宜
着色剤、香料などを加え精製水で規定量とする方法が挙
げられるが、とくに限定されるものではなく、あらゆる
内用液剤の製剤形態に適した通常の方法を用いることが
できる。[0014] As a method for preparing the syrup of the present invention, for example, sodium ascorbate, pH
As a conditioning agent, sodium hydrogen carbonate is added and dissolved in purified water under nitrogen substitution, and separately purified water is added to flavoring agents, preservatives, or other medicinal ingredients as necessary, and dissolved by heating etc. An example of this method is to mix and stir under nitrogen purge, add coloring agents, fragrances, etc. as appropriate, and make up the specified amount with purified water, but there are no particular limitations. A method can be used.
【0015】具体的には、 たとえば、 まず精製水1
75Lにパラオキシ安息香酸メチルなどの保存剤を加え
加熱して溶かし、これに白糖250kgを加え加熱溶解
する。
ついで、 炭酸水素ナトリウム1. 4kg及び他の薬
効成分、たとえば、アセトアミノフェンなどを加え、必
要ならば加温して溶解する。Specifically, for example, first, purified water 1
Add a preservative such as methyl paraoxybenzoate to 75 liters and heat to dissolve. Add 250 kg of white sugar to this and heat to dissolve. Next, sodium hydrogen carbonate 1. 4 kg and other medicinal ingredients, such as acetaminophen, are added and dissolved by heating if necessary.
【0016】次いで、この液を冷却し(30℃以下)窒
素置換下でアスコルビン酸ナトリウムを加え溶解する。
つぎに、香料を窒素置換下で加え全量を500Lとし、
pH7. 5の本発明のシロップ剤をえる。[0016] Next, this liquid is cooled (below 30°C), and sodium ascorbate is added and dissolved under nitrogen substitution. Next, add fragrance under nitrogen substitution to bring the total volume to 500L.
pH7. 5 of the syrup of the present invention is obtained.
【0017】本発明のシロップ剤は、後記保存試験(試
験例2)の結果から有効成分であるアスコルビン酸ナト
リウムの含量が室温3年で10%以下の減少しかみられ
ないと判断され、医薬品として広く供給されうるもので
ある。[0017] Based on the results of the storage test (Test Example 2) described below, it was determined that the content of the active ingredient, sodium ascorbate, in the syrup of the present invention decreased by less than 10% over a period of 3 years at room temperature, and therefore it cannot be used as a pharmaceutical product. It can be widely supplied.
【0018】[0018]
【実施例】つぎに、実施例にもとづいて本発明をさらに
詳しく説明するが、本発明はもとよりこれらに限定され
るものではない。
実施例1
アスコルビン酸ナトリウム含有シロップ剤を下記の処方
にしたがって窒素置換下(酸素濃度約4%)で調製した
後、炭酸水素ナトリウムを用いて、pHが、6. 0,
7. 0及び8. 0となるように調整し褐色瓶に充
填し、窒素を封入(酸素濃度約4%)し、サンプルを作
製し封かんした。[Examples] Next, the present invention will be explained in more detail based on Examples, but the present invention is not limited to these. Example 1 A syrup containing sodium ascorbate was prepared according to the following recipe under nitrogen substitution (oxygen concentration of about 4%), and then adjusted to pH 6.0 using sodium hydrogen carbonate. 0,
7. 0 and 8. It was adjusted to 0 and filled into a brown bottle, filled with nitrogen (oxygen concentration of about 4%), and a sample was prepared and sealed.
【0019】(処方)
アスコルビン酸ナトリウム 7g白糖
75
0gパラオキシ安息香酸メチル 250mg精製
水
適量全量 1500g
なお前記処方にしたがって調製されたシロップ剤の性状
は無色のやや粘稠な液である。(Prescription) Sodium ascorbate 7g White sugar
75
0g methyl paraoxybenzoate 250mg purified water
Appropriate amount: 1500 g The syrup prepared according to the above recipe is a colorless, slightly viscous liquid.
【0020】比較例1.実施例1と同一処方にて窒素置
換下で調製した後、炭酸水素ナトリウムを用いて、 p
Hが、5. 0となるように調整し褐色瓶に充填し、窒
素を封入(酸素濃度約4%)し、サンプルを作製し封か
んした。Comparative Example 1. After preparing with the same recipe as in Example 1 under nitrogen substitution, using sodium hydrogen carbonate, p
H is 5. It was adjusted to 0 and filled into a brown bottle, filled with nitrogen (oxygen concentration of about 4%), and a sample was prepared and sealed.
【0021】試験例1.実施例1,比較例1のサンプル
について40℃及び50℃において、アスコルビン酸ナ
トリウムの経時的含量変化の測定を加速試験にて行った
。アスコルビン酸ナトリウム含量は後記アスコルビン酸
の定量法にしたがって測定した。1箇月および2箇月後
の40℃および50℃におけるシロップ剤のアスコルビ
ン酸の残存率を表−1に示す。Test Example 1. For the samples of Example 1 and Comparative Example 1, changes in sodium ascorbate content over time were measured at 40°C and 50°C in an accelerated test. The sodium ascorbate content was measured according to the ascorbic acid quantitative method described below. Table 1 shows the residual rate of ascorbic acid in the syrup at 40°C and 50°C after one month and two months.
【0022】[0022]
【表1】
その結果、実施例1のpH6. 0〜8. 0の範囲の
シロップ剤が安定であるといえる。[Table 1] As a result, the pH of Example 1 was 6. 0-8. It can be said that syrups in the range of 0 are stable.
【0023】実施例2.アスコルビン酸ナトリウム含有
シロップ剤(pH7.5)を、下記の処方にしたがって
窒素置換下(酸素濃度約4%)で調製し、60ml褐色
瓶に充填し、更に容器の空間に窒素を封入し密栓した。Example 2. A syrup containing sodium ascorbate (pH 7.5) was prepared according to the following recipe under nitrogen substitution (oxygen concentration of about 4%), filled into a 60 ml amber bottle, and the space of the container was further filled with nitrogen and sealed. .
【0024】(処方)
アスコルビン酸ナトリウム 4
0gアセトアミノフェン
60g白糖
3500g炭酸水素ナトリウ
ム 20gパラオ
キシ安息香酸ナトリウム 1g精製
水
適量全量 7000ml
なお、上記処方にしたがって調製されたシロップ剤の性
状は、無色のやや粘稠な液である。(Prescription) Sodium ascorbate 4
0g acetaminophen
60g white sugar
3500g Sodium bicarbonate 20g Sodium paraoxybenzoate 1g Purified water
Appropriate amount: 7000 ml The syrup prepared according to the above recipe is a colorless, slightly viscous liquid.
【0025】試験例2.実施例2のサンプルを25℃お
よび40℃の恒温器に放置し、アスコルビン酸ナトリウ
ムの経時的含量変化の測定(後記アスコルビン酸の定量
法参照)を行った。40℃保存下、1,2,3,6箇月
後、及び25℃保存下12,36箇月後におけるシロッ
プ剤のアスコルビン酸ナトリウムの残存率を表−2に示
す。Test Example 2. The sample of Example 2 was left in a constant temperature chamber at 25° C. and 40° C., and the change in content of sodium ascorbate over time was measured (see the method for quantifying ascorbic acid described below). Table 2 shows the residual rate of sodium ascorbate in the syrup after 1, 2, 3, and 6 months of storage at 40°C, and 12 and 36 months of storage at 25°C.
【0026】[0026]
【表2】
この結果、25℃,36箇月の保存において90%以上
の含量を維持しており、更に40℃,6箇月(25℃、
3年に相当)の保存においても90%以上の含量を維持
していることから、本シロップ剤は25℃で3年の安定
性を保証できると考える。[Table 2] As a result, the content was maintained at 90% or more after storage at 25℃ for 36 months, and after storage at 40℃ for 6 months (25℃,
Since the content was maintained at over 90% even after storage for 3 years (equivalent to 3 years), we believe that this syrup can guarantee stability for 3 years at 25°C.
【0027】(アスコルビン酸の定量法)本発明のシロ
ップ剤に有効成分として含有されているアスコルビン酸
又はその塩類又はその誘導体の含量は下記に示す方法に
て測定した。方法:アスコルビン酸又はその塩類又はそ
の誘導体を含む本品を一定量正確に量り取り、必要であ
れば加水分解等の前処理を施し、メタリン酸・酢酸試液
および過酸化水素試液を加えて振り混ぜた後、滴定用2
,6−ジクロルフェノールインドフェノールナトリウム
試液で液が5秒間持続する淡紅色を呈するまで滴定する
。(Ascorbic acid determination method) The content of ascorbic acid, its salts, or its derivatives contained as an active ingredient in the syrup of the present invention was determined by the method shown below. Method: Accurately measure a certain amount of this product containing ascorbic acid, its salts, or its derivatives, perform pretreatment such as hydrolysis if necessary, add metaphosphoric acid/acetic acid test solution and hydrogen peroxide test solution, and shake. After that, titration 2
, 6-dichlorophenol Indophenol sodium test solution until the solution exhibits a light pink color that lasts for 5 seconds.
【0028】[0028]
【発明の効果】本発明のアスコルビン酸又はその塩類又
はその誘導体含有シロップ剤は室温で通常保存において
長期にわたり、有効成分であるアスコルビン酸又はその
塩類又はその誘導体がその含量において経時的に減少す
ることが無い長期安定なものである。したがって、医療
はもちろん、一般用医薬品として広く利用されるという
効果をもたらす。Effects of the Invention: The syrup containing ascorbic acid, its salts, or its derivatives of the present invention can be stored normally for a long period of time at room temperature, and the content of the active ingredient ascorbic acid, its salts, or its derivatives decreases over time. It is stable over a long period of time. Therefore, it has the effect of being widely used not only in medical treatment but also as an over-the-counter drug.
Claims (2)
誘導体を有効成分とし、かつpHが6. 0〜8. 0
の範囲に調整されていることを特徴とするシロップ剤。Claim 1: The active ingredient is ascorbic acid, a salt thereof, or a derivative thereof, and the pH is 6. 0-8. 0
A syrup agent characterized by being adjusted to a range of.
ていることを特徴とする請求項1記載のシロップ剤。[Claim 2] pH is 7. 0-8. The syrup according to claim 1, wherein the syrup is adjusted to 0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14685291A JPH04346926A (en) | 1991-05-21 | 1991-05-21 | Syrup agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14685291A JPH04346926A (en) | 1991-05-21 | 1991-05-21 | Syrup agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04346926A true JPH04346926A (en) | 1992-12-02 |
Family
ID=15417006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14685291A Pending JPH04346926A (en) | 1991-05-21 | 1991-05-21 | Syrup agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04346926A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0982990A4 (en) * | 1998-02-06 | 2001-05-16 | Oxycal Lab Inc | Stable liquid mineral ascorbate compositions and methods of manufacture and use |
WO2003070021A1 (en) * | 2002-02-25 | 2003-08-28 | Mic Co., Ltd. | Nutritionally enriched maple syrup |
GB2450477A (en) * | 2007-06-18 | 2008-12-31 | Ethicon Inc | Stabilized wound dressing |
-
1991
- 1991-05-21 JP JP14685291A patent/JPH04346926A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0982990A4 (en) * | 1998-02-06 | 2001-05-16 | Oxycal Lab Inc | Stable liquid mineral ascorbate compositions and methods of manufacture and use |
JP2002513426A (en) * | 1998-02-06 | 2002-05-08 | オキシカル・ラボラトリーズ,インコーポレイテッド | Stable liquid mineral ascorbate compositions and methods of making and uses |
JP4717166B2 (en) * | 1998-02-06 | 2011-07-06 | ザ・エスター・シー・カンパニー | Stable liquid mineral ascorbate composition and method and use |
WO2003070021A1 (en) * | 2002-02-25 | 2003-08-28 | Mic Co., Ltd. | Nutritionally enriched maple syrup |
GB2450477A (en) * | 2007-06-18 | 2008-12-31 | Ethicon Inc | Stabilized wound dressing |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP957A (en) | Novel stable liquid paracetamol compositions, and method for preparing same. | |
JP4717166B2 (en) | Stable liquid mineral ascorbate composition and method and use | |
JP4959006B2 (en) | Hesperidin-containing composition | |
EP1465663A1 (en) | Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent | |
JP4393192B2 (en) | Ribavirin syrup formulation | |
JPH04346926A (en) | Syrup agent | |
US5411993A (en) | Anti-inflammatory, stable aqueous preparation comprising azulene sodium sulfonate and polyhydric alcohol | |
JPS6245202B2 (en) | ||
JPH11246513A (en) | Aqueous liquid agent of azulene | |
US3306824A (en) | Dietary fluoride and vitamin preparations | |
GB2185887A (en) | Temazepam composition | |
JPS6146454B2 (en) | ||
JP2007106736A (en) | Pharmaceutical composition for parenteral injection | |
JPH03120212A (en) | Effervescent preparation | |
WO2024095311A1 (en) | Compound containing ascorbic acid derivative | |
JP2002097141A (en) | Aqueous solution of vitamin b | |
US11617730B2 (en) | Pharmaceutical formulation for administering paracetamol by buccal/gingival route | |
JPH07116039B2 (en) | Stable Trimethoquinol Hydrochloride Internal Solution | |
JPH0621061B2 (en) | Clear gel formulation containing urea stably | |
Goel et al. | Pharmaceutical excipients | |
JPH07258165A (en) | Method for stabilizing aqueous solution of gamma-oryzanol and stabilized aqueous solution of gamma-oryzanol | |
JPH01221312A (en) | Oral liquid containing fat-soluble substance | |
CA3213851A1 (en) | Liquid preparation of l-serine or pharmaceutically acceptable salt thereof and method for preparing same | |
JPH0952845A (en) | Enzyme-containing internal liquid medicine having high shelf stability | |
JP2003192574A (en) | Liquid medicine containing medicament stabilized in weak alkali |